June 26, 2024

The Honorable Tammy Baldwin                             The Honorable Robert Aderholt
Chairwomen                                               Chairman
United States Senate                                     U.S. House of Representatives
Washington, DC  20510                                   Washington, DC  20515

The Honorable Shelley Moore Capito                       The Honorable Rosa DeLauro
Ranking Member                                           Ranking Member
United States Senate                                     U.S. House of Representatives
Washington, DC  20510                                   Washington, DC  20515

Dear Chairwoman Baldwin, Ranking Member Moore Capito, Chairman Aderholt, and Ranking Member DeLauro,

On behalf of the undersigned 16 organizations dedicated to improving prevention, care, and treatment for the nearly 100 million Americans affected by liver disease, we extend our gratitude for your leadership and dedication to funding research aimed at enhancing healthcare safety, quality, accessibility, equity, and affordability at the Agency for Healthcare Research and Quality (AHRQ).

The detection, prevention, and research of liver disease demand immediate attention. Metabolic dysfunction-associated liver disease (MASLD), affects between 80 and 100 million Americans, with most remaining undiagnosed. MASLD is present in up to 75% of overweight people and in more than 90% of people with severe obesity. The more metabolic risk factors someone has, such as obesity, diabetes and hypertension, the more risk they also have for developing advanced liver disease. In fact, the top two risk factors for developing MASLD are obesity and type 2 diabetes, and the number one cause of death in those with MASLD, is cardiovascular disease.

MASLD has become the most common form of childhood liver disease in the U.S., more than doubling over the past 20 years, partly because of the increase in childhood obesity. Studies estimate that 5% to 10% of children in the U.S. have MASLD. MASLD also disproportionately affects Hispanic communities, with MASLD prevalence among Hispanic/Latino people reaching 58.3%, compared to 44.6% in White people and 35.1% in Black/African American people. Additionally, Asian American and Pacific Islander (AAPI) communities also face significant liver health disparities, with high prevalence rates of MASLD due to genetic predispositions and metabolic risk factors.

Left untreated, MASLD can progress to its more dangerous and life-threatening form, metabolic dysfunction-associated steatohepatitis (MASH), which includes fibrosis or scarring of the liver that can lead to liver cancer and liver failure. MASH is expected to become the leading cause of all liver transplantations by 2025.
Given these pressing challenges, liver disease warrants focused attention from both the U.S. Congress and Administration. The FY24 Labor-HHS bill included language urging AHRQ to conduct a study on MASLD, assessing its prevalence, diagnosis, and treatment options. These findings will be pivotal in comprehending the impact of liver disease, thereby guiding preventive measures against liver cancer, liver failure, and the need for transplantation.

To combat the escalating public health crisis posed by liver disease, we implore you to augment crucial funding for AHRQ in the Fiscal Year 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriations Bills, aligning with the President’s proposed budget of $387 million for AHRQ. The enacted appropriation for FY24 of $369 million for AHRQ was a $5 million decrease from FY23, which hinders AHRQ’s ability to address critical healthcare challenges, including liver disease.

Acknowledging that liver disease ranks as the 12th leading cause of death in the United States, it is imperative that AHRQ receives adequate funding. A failure to sufficiently fund AHRQ risks hindering essential research endeavors and exacerbating the burden of liver disease on nearly 100 million Americans. Therefore, we strongly urge you to allocate $387 million for the Agency for Healthcare Research and Quality in FY2025, representing an $18 million increase over FY2024.

The signed organizations look forward to working with you and your colleagues this year as you maintain the federal government’s commitment to improving and sustaining health and wellbeing in our country. Should you have any questions, please contact Valerie Rinck at American Liver Foundation, vrinck@liverfoundation.org.

Thank you again for your leadership. We are enthusiastic about the positive changes we can achieve in the lives of those affected by liver disease.

Signed,

American Association for the Study of Liver Diseases (AASLD)  Migrant Clinicians Network, Inc.
American Diabetes Association  NASH kNOWledge
American Liver Foundation  NASTAD
American Society of Transplantation  National Association of Hispanic Nurses
American Society of Transplant Surgeons  National Association of Nurse Practitioners in Women’s Health (NPWH)
BlackDoctor.org  Obesity Action Coalition
Hepatitis B Foundation  Society of Interventional Radiology
Hepatology section of the University of Michigan  University of Pennsylvania